FDA Approves NovoLog for Use in Children and Adolescents

Novo Nordisk announced that the U.S. Food and Drug Administration has approved NovoLog (insulin aspart [rDNA origin] injection) for continuous subcutaneous insulin infusion (CSII) by external insulin pump in pediatric patients between the ages of 4 and 18 years.
CNN Money